A new study investigating a single dose of psilocybin for the treatment of major depressive disorder (MDD) has shown clinically significant levels of reduction in depressive...
Japanese pharmaceutical company Otsuka Pharmaceutical has made one of Big Pharma’s first pivots into the psychedelics space with the acquisition of Mindset Pharma.
Launching in 2008 as a drug literature review blog by Rob Dickins, Psychedelic Press has brought readers a host of unique insights into psychedelic thought and...
With a rise in clinical trials investigating psychedelics for a number of mental health conditions, the UK’s Parliamentary Office of Science and Technology (POST) has issued...
UK-based COMPASS Pathways has secured $285 million in funding through a private placement to support its research in psychedelic medicines.
Returning for its fourth year, Medicine Festival is set to host some of the world’s leading psychedelic researchers alongside indigenous elders from across the globe.
The first-ever Professional Practice Guidelines for psychedelic therapy in the US have been published by the American Psychedelic Practitioners Association (APPA) and BrainFutures.
Marking a world first, researchers at Imperial’s Centre for Psychedelic Research will investigate psilocybin as a treatment for gambling addiction with the support of funding from...
Silo Pharma has announced it has advanced the formulation development for its therapeutic drug, SPC-15, which utilises ketamine.
A new Phase 1 study looking at psilocybin in combination with psychological support as a treatment for females with anorexia nervosa has shown positive results.